HLB Therapeutics Co.,Ltd. (HLB Therapeutics) aktie

HLB Therapeutics Co.,Ltd., a biotech company, develops pharmaceutical products in South Korea and internationally. It is developing GBT-201 using Thymosin beta for the treatment of ophthalmic diseases, such as dry eye syndrome and neurotrophic keratopathy; and OKN-007 for the treatment of glioblastoma brain tumor. It is also involved in the wholesale of vaccines, as well as manufactures electrical and electronic components, such as motors, pumps, and transformers. The company was formerly known as G-treeBNT Co., Ltd. and changed its name to HLB Therapeutics Co.,Ltd. in December 2021. HLB Therapeutics Co.,Ltd. was founded in 2000 and is headquartered in Seongnam-si, South Korea.